netFormulary Chelsea and Westminster Hospital NHS
NHS Foundation Trust  
 Search
 Results

Looking for Adalimumab found 40 matches

Formulary items 14 matches
   
Open monograph to display formulary status BNF Category
  Adalimumab  (Humira®)
(Gastroenterology)
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Adalimumab  (Humira®)
(Dermatology)
Skin - Drugs affecting the immune response - 13.05.03
  Adalimumab  (Humira® Amgevita®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Abatacept  (Orencia®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Certolizumab Pegol  (Cimzia®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Etanercept  (Enbrel®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Etanercept  (Enbrel®)
(Dermatology)
Skin - Drugs affecting the immune response - 13.05.03
  Golimumab  (Simponi®)
(Gastroenterology)
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Golimumab  (Simponi®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Infliximab  (Remicade®)
(For use in line with NICE guidance)
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Infliximab  (Remicade® Remsima®)
(Gastroenterology)
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Rituximab  (MabThera®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Tocilizumab  (RoActemra®) Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Ustekinumab  (Stelara®) Skin - Drugs affecting the immune response - 13.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in subsection NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA146: Psoriasis - adalimumab (13.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis  (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (10.01.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)


 

netFormulary